Dibyangana D. Bhattacharyya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dibyangana D. Bhattacharyya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Sharon A. Glynn
Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland
2 shared publications - Aideen E. Ryan
Discipline of Pharmacology and Therapeutics, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland
1 shared publication - Christopher L. McGinity
Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
1 shared publication - Daniel W. McVicar
Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, Frederick MD 21702, USA
1 shared publication - David A. Wink
Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, USA
1 shared publication - Douglas D. Thomas
Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
- 30 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7068
Nitric Oxide Modulates Metabolic Processes in the Tumor Immune Microenvironment
The metabolic requirements and functions of cancer and normal tissues are vastly different. Due to the rapid growth of cancer cells in the tumor microenvironment, distorted vasculature is commonly observed, which creates harsh environments that require rigorous and constantly evolving cellular adaption. A common hallmark of aggressive and therapeutically resistant tumors is hypoxia and hypoxia-induced stress markers. However, recent studies have identified alterations in a wide spectrum of metabolic pathways that dictate tumor behavior and response to therapy. Accordingly, it is becoming clear that metabolic processes are not uniform throughout the tumor microenvironment. Metabolic processes differ and are cell type specific where various factors promote metabolic heterogeneity within the tumor microenvironment. Furthermore, within the tumor, these metabolically distinct cell types can organize to form cellular neighborhoods that serve to establish a pro-tumor milieu in which distant and spatially distinct cellular neighborhoods can communicate via signaling metabolites from stroma, immune and tumor cells. In this review, we will discuss how biochemical interactions of various metabolic pathways influence cancer and immune microenvironments, as well as associated mechanisms that lead to good or poor clinical outcomes.
- 30 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 7068
Open AccessNitric Oxide Modulates Metabolic Processes in the Tumor Immune Microenvironment
The metabolic requirements and functions of cancer and normal tissues are vastly different. Due to the rapid growth of cancer cells in the tumor microenvironment, distorted vasculature is commonly observed, which creates harsh environments that require rigorous and constantly evolving cellular adaption. A common hallmark of aggressive and therapeutically resistant tumors is hypoxia and hypoxia-induced stress markers. However, recent studies have identified alterations in a wide spectrum of metabolic pathways that dictate tumor behavior and response to therapy. Accordingly, it is becoming clear that metabolic processes are not uniform throughout the tumor microenvironment. Metabolic processes differ and are cell type specific where various factors promote metabolic heterogeneity within the tumor microenvironment. Furthermore, within the tumor, these metabolically distinct cell types can organize to form cellular neighborhoods that serve to establish a pro-tumor milieu in which distant and spatially distinct cellular neighborhoods can communicate via signaling metabolites from stroma, immune and tumor cells. In this review, we will discuss how biochemical interactions of various metabolic pathways influence cancer and immune microenvironments, as well as associated mechanisms that lead to good or poor clinical outcomes.
- 1 January 2020
- Published by Elsevier
- p. 95-113
A review of RKIP promotion of tumor progression, metastasis and poor outcome in multiple solid tumor types
- 1 January 2020
- Published by Elsevier
- p. 95-113
A review of RKIP promotion of tumor progression, metastasis and poor outcome in multiple solid tumor types